[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E: Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer; 2005 Oct 15;104(8):1580-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
  • BACKGROUND: The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes.
  • METHODS: Two hundred forty-six patients with AJCC Stage IIA, IIB, or IIIA breast carcinoma who had > or = 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B (CALGB) 9082 were enrolled in this companion study, CALGB 9066.
  • QOL was assessed at baseline and at 3 months, 12 months, 24 months, and 36 months using the Functional Living Index-Cancer (FLIC), the Psychosocial Adjustment to Illness Scale (PAIS)-Self Report, and the McCorkle Symptom Distress Scale (SDS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Breast Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16118805.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31809; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA37135; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA47545; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


2. Kimmick GG, Shelton BJ, Case LD, Cooper MR, Muss HB: Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. Breast Cancer Res Treat; 2002 Apr;72(3):233-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast.
  • BACKGROUND: Combination chemotherapy improves outcomes in women with breast cancer (BC) that involves axillary nodes.
  • This single-arm study aimed to evaluate the effectiveness of an intensive doxorubicin-based multidrug regimen as adjuvant therapy in women with stage II, node positive breast cancer.
  • PATIENTS AND METHODS: Between 7/80 and 8/85, 654 women, aged 25-73, who had a mastectomy for stage IIB BC were accrued.
  • Treatment consisted of: 6 weekly courses of IV cyclophosphamide (C) 400 mg/m2, doxorubicin (A) 10 mg/m2, vincristine (V) I mg/m2, fluorouracil (F) 400 mg/m2, and a tapering course of prednisone followed by 12 courses of C 400 mg/m2, A 20mg/m2, V 1 mg/m2, F 400 mg/m2 given every 2 weeks.
  • [MeSH-major] Adjuvants, Pharmaceutic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Doxorubicin / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12058965.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-12197; United States / NCI NIH HHS / CA / CA-33499
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 80168379AG / Doxorubicin
  •  go-up   go-down


3. Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS: Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat; 2008 Nov;112(1):123-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer recurrence risk in relation to antidepressant use after diagnosis.
  • BACKGROUND: While laboratory data suggest that antidepressants may promote mammary tumor growth, there has been little research investigating whether antidepressant use after breast cancer diagnosis is associated with the risk of breast cancer recurrence.
  • Women diagnosed with a first primary invasive, stage I, IIA, or IIB, unilateral breast carcinoma between 1990-1994 (aged>or=65 years) and 1996-1999 (aged>or=18 years) were eligible for the study (N=1306).
  • We used multiple Cox regression to estimate the hazard ratio for recurrence and breast cancer mortality, comparing users and non-users of antidepressant medications.
  • RESULTS: We did not observe an association between antidepressant use after breast cancer diagnosis and the risk of recurrence either in general (hazard ratio for any antidepressant use: 0.8; 95% confidence interval: 0.5-1.4) or for specific types of antidepressant medication.
  • Risk of death from breast cancer did not differ between non-users and users of antidepressants.
  • CONCLUSIONS: The results of this study suggest that women who use antidepressants after breast cancer diagnosis do not have an increased risk of recurrence or mortality.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):236S-242S [17182833.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4377-83 [16983106.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):966-74 [17243096.001]
  • [Cites] Clin Ther. 2007 Feb;29(2):230-41 [17472816.001]
  • [Cites] Eur J Epidemiol. 2007;22(5):319-25 [17487555.001]
  • [Cites] BMC Med Res Methodol. 2007;7:23 [17577410.001]
  • [Cites] Qual Life Res. 2007 Aug;16(6):947-60 [17457697.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3428-36 [17687148.001]
  • [Cites] Breast Cancer Res Treat. 2007 Oct;105(2):209-19 [17203386.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):319-23 [10750671.001]
  • [Cites] Am J Epidemiol. 2000 May 15;151(10):951-7 [10853633.001]
  • [Cites] Psychiatry Res. 2000 Jul 24;95(1):25-34 [10904120.001]
  • [Cites] J Public Health Med. 2000 Jun;22(2):155-60 [10912553.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):754-62 [11353785.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):130-4 [11773306.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):92-7 [11857018.001]
  • [Cites] Curr Drug Metab. 2002 Feb;3(1):13-37 [11876575.001]
  • [Cites] Cancer Causes Control. 2002 Feb;13(1):35-45 [11899116.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3302-16 [12149305.001]
  • [Cites] J Clin Epidemiol. 2003 Feb;56(2):155-63 [12654410.001]
  • [Cites] Support Care Cancer. 2003 May;11(5):278-85 [12720073.001]
  • [Cites] Psychother Psychosom. 2003 Jul-Aug;72(4):185-94 [12792123.001]
  • [Cites] Epidemiology. 2003 May;14(3):307-14 [12859031.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64 [14652237.001]
  • [Cites] Int J Epidemiol. 2003 Dec;32(6):961-6 [14681256.001]
  • [Cites] Gen Hosp Psychiatry. 2004 Mar-Apr;26(2):121-8 [15038929.001]
  • [Cites] J Clin Pharmacol. 2004 Aug;44(8):861-5 [15286089.001]
  • [Cites] JAMA. 2004 Oct 6;292(13):1581-7 [15467060.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4184-92 [15483029.001]
  • [Cites] Arch Intern Med. 1972 Sep;130(3):349-54 [4560178.001]
  • [Cites] Life Sci. 1975 Oct 10;17(7):1141-4 [1081634.001]
  • [Cites] Oncology. 1982;39(5):279-83 [7099510.001]
  • [Cites] Am J Epidemiol. 1982 Aug;116(2):329-32 [7114041.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4025-31 [2886214.001]
  • [Cites] Biol Psychiatry. 1989 Dec;26(8):805-17 [2590693.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):147-52 [1986602.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1842-7 [1888251.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3796-800 [1617649.001]
  • [Cites] Psychopharmacol Bull. 1993;29(2):149-54 [8290659.001]
  • [Cites] Arch Gen Psychiatry. 1995 Feb;52(2):89-99 [7848055.001]
  • [Cites] J Clin Epidemiol. 1995 Nov;48(11):1407-12 [7490604.001]
  • [Cites] Psychosom Med. 1997 May-Jun;59(3):280-93 [9178339.001]
  • [Cites] CMAJ. 1998 Feb 10;158 Suppl 3:S71-81 [9484281.001]
  • [Cites] Clin Pharmacol Ther. 1998 May;63(5):594-9 [9630832.001]
  • [Cites] Am J Epidemiol. 1999 Oct 15;150(8):861-8 [10522657.001]
  • [Cites] Obstet Gynecol. 2004 Nov;104(5 Pt 1):1042-50 [15516400.001]
  • [Cites] Epidemiology. 2005 Jan;16(1):101-5 [15613952.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):30-9 [15632378.001]
  • [Cites] Cancer Lett. 2005 Apr 18;221(1):61-5 [15797628.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1710-4 [16098457.001]
  • [Cites] Am J Epidemiol. 2005 Nov 1;162(9):835-8 [16177141.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9312-8 [16361630.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(2):131-40 [16322894.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1071-8 [16523201.001]
  • [Cites] Clin Pharmacol Ther. 2006 Jul;80(1):61-74 [16815318.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(1):113-21 [17115111.001]
  • (PMID = 18058227.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093772; United States / NCI NIH HHS / CA / T32 CA009168; United States / NCI NIH HHS / CA / R01 CA09377; United States / NCI NIH HHS / CA / T32 CA09168
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antidepressive Agents
  • [Other-IDs] NLM/ NIHMS423184; NLM/ PMC3519424
  •  go-up   go-down


Advertisement
4. Moyses B, Haegele P, Rodier JF, Lehmann S, Petit T, Velten M, Schraub S: Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer. Clin Breast Cancer; 2002 Jan;2(4):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
  • Breast helical computed tomography (CT) was evaluated for use in assessing response to neoadjuvant chemotherapy and residual tumor volume.
  • Forty-three patients with large, inflammatory breast cancers (stage IIA, 12; IIB, 13; IIIA, 9; IIIB, 9), all histologically confirmed by core biopsy, were evaluated prior to and following neoadjuvant chemotherapy.
  • The breast helical CT procedure involved patients in the prone position using single acquisition during quiet respiration following intravenous injection of nonionic contrast material.
  • All tumors were clearly visible by breast helical CT, showing important tumor enhancement.
  • Breast helical CT can be very useful in the quantitative assessment of response to neoadjuvant chemotherapy and preoperative determination of residual tumor volume.
  • For this reason, it can be considered an alternative to breast magnetic resonance imaging because of its simplicity, rapidity, and accessibility.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Ductal, Breast / diagnostic imaging. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / diagnostic imaging. Carcinoma, Lobular / drug therapy. Drug Monitoring / methods. Neoadjuvant Therapy. Paclitaxel / analogs & derivatives. Taxoids. Tomography, X-Ray Computed / standards. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy, Needle. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Mammography / standards. Mastectomy. Middle Aged. Mitoxantrone / administration & dosage. Physical Examination / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11899363.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Nakaguchi K, Furukawa J, Maruyama N, Nakamura M, Shingai T, Maruyama K, Katsumoto Y, Okajima S, Sue F, Yoshiwara W: [A case of recurring breast cancer causing pericardial metastasis showing a good response following local treatment with methotrexate]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1753-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurring breast cancer causing pericardial metastasis showing a good response following local treatment with methotrexate].
  • She had undergone right mastectomy for Stage IIB breast cancer 2 years and five months earlier.
  • A diagnosis of cardiac tamponade was made and pericardiocentesis for continuous drainage was carried out cytologically, the effusion was class V and showed evidence of pericardial metastasis of breast cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Breast Neoplasms / pathology. Heart Neoplasms / drug therapy. Heart Neoplasms / secondary. Methotrexate / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cardiac Tamponade / etiology. Cyclophosphamide / administration & dosage. Drainage. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Pericardial Effusion / etiology. Pericardial Effusion / therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11708026.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; FEC protocol
  •  go-up   go-down


6. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer; 2008 Feb 26;8:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
  • BACKGROUND: In recent years, preoperative volume reduction of locally advanced breast cancers, resulting in higher rates of breast-conserving surgery (BCS), has become increasingly important also in postmenopausal women.
  • METHODS: This study was designed as a multicenter, open-label, single-arm, exploratory phase IIb/III clinical trial of letrozole 2.5 mg, one tablet daily, for 4-8 months.
  • RESULTS: Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67.0 (56-85) years) with unilateral, initially BCS-ineligible primary breast cancer (clinical stage > or = T2, N0, M0).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Nitriles / administration & dosage. Postmenopause / metabolism. Triazoles / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / surgery. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Mammography. Mastectomy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Preoperative Care. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2596-606 [11352951.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):191-9 [11510690.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2620-35 [11555572.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3808-16 [11559718.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1527-32 [11822750.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):103-7 [11850213.001]
  • [Cites] Onkologie. 2006 May;29(5):210-7 [16679783.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3554-6 [12913101.001]
  • [Cites] N Engl J Med. 1985 Mar 14;312(11):674-81 [3883168.001]
  • [Cites] Eur J Cancer. 1992;28A(4-5):908-10 [1524922.001]
  • [Cites] Eur J Surg Oncol. 1994 Jun;20(3):207-14 [8181594.001]
  • [Cites] Anticancer Res. 1994 Sep-Oct;14(5B):2197-200 [7840523.001]
  • [Cites] Breast. 2006 Feb;15(1):9-19 [16230013.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2431-42 [12802030.001]
  • (PMID = 18302747.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00535418
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Triazoles; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ PMC2270851
  •  go-up   go-down


7. de la Cueva L, Liévano P, Navarro P, Arroyo E, Añaños M, González M, García MC, Fuerte A, Colmenarejo F, Baringo T, Abós MD: [Indication for bone scans in early breast cancer staging]. Rev Esp Med Nucl; 2009 Nov-Dec;28(6):273-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication for bone scans in early breast cancer staging].
  • [Transliterated title] Indicación del rastreo óseo en la estadificación del cáncer de mama de inicio.
  • OBJECTIVE: Evaluate the indication for bone scanning during staging of early breast cancer in the light of scientific evidence to assess the need to modify practices with scant effectiveness.
  • MATERIAL AND METHODS: The bone scans carried out in our Nuclear Medicine Department in 2007 on patients with primary breast cancer were reviewed retrospectively.
  • Bone scan results of tumors >2 cm y <or=5 cm (T2) were analyzed in two groups stratified by tumor size, <or=3 cm or >3 cm, and pre-treatment clinical stage.
  • RESULTS: Out of 245 bone scans of patients with breast cancer, 237 (97%) were negative for metastatic disease and 8 (3%) were positive.
  • There were no differences in the rate of bone metastases in patients with stage T2 disease and lesions <or=3 cm vs. >3 cm.
  • The bone scan findings did not modify staging in any of the 66 patients with T2 tumors stage IIA, but it did modify staging in 2 of 12 patients with stage IIB tumors.
  • CONCLUSIONS: Ineffective practices should be modified and bone scanning should not be indicated in patients with early breast cancer Tis, T1 and T2 with tumor <or=2 cm, clinical stage IIA.
  • Pre-treatment bone scanning is still indicated in T2 IIB, T3 and T4 disease.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma / radionuclide imaging. Carcinoma / secondary. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995533.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


8. Târcoveanu E, Lupaşcu C, Vasilescu A, Moldovanu R, Ichim M, Georgescu S, Niculescu D, Dănilă N, Dimofte G, Anton R, Crumpei F, Florea N, Ungureanu C: [Surgical treatment of gynecomastia]. Chirurgia (Bucur); 2008 Nov-Dec;103(6):643-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the results after surgical treatment (mastectomy) performed in a general surgery unit.
  • The clinical, imaging, biological, intraoperative and histological data were included into a MS Access database and statistical analyzed.
  • Simon classification was used for preoperative staging: 2.6% from the cases (N = 3) were included in stage I, 16.7% (N = 19) in stage IIa, 50% (N = 57) in stage IIb and 30.7% in stage III.
  • The patients included in stages IIa and I are younger then the patients included in stage III (p = 0.024).
  • Most of the cases were operated using general anesthesia (53.5%).
  • The subdermal mastectomy using peri-areolar approach was performed especially for the cases included in stages I, IIa and IIb--p < 10(-3).
  • The histological exam also revealed intraductal papilloma--9 cases, fibro-adenoma--1 case, papillary ductal carcinoma--1 case and mucinous carcinoma--1 case.
  • From all these data, the etiological diagnosis in presented series was: pseudo-gynecomastia--5.3% (N = 6), idiopathic--64.9% (N = 73), endocrine--7.9% (N = 9), drug induce--5.3% (N = 6), metabolic--7.9% (N = 9), tumoral--8.8% (N = 10).
  • Gynecomastia it is possible to be associated with a breast cancer, even in younger people.
  • The surgical treatment, especially the type of incision, will be chosen from point of view of Simon stages.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Child. Humans. Lipectomy / methods. Male. Middle Aged. Preoperative Care. Retrospective Studies. Risk Factors. Tamoxifen / therapeutic use. Treatment Outcome

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274908.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


9. Wilson NM, Espirito JL, Valero V, Pusztai L: Paclitaxel-induced sickle cell crisis. Am J Health Syst Pharm; 2008 Jul 15;65(14):1333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A case of paclitaxel-induced painful crisis in a patient with breast cancer and hemoglobin sickle cell disease (SCD) is reported.
  • SUMMARY: A 55-year-old postmenopausal African-American woman had stage IIB invasive ductal carcinoma of the left breast.
  • She was not taking any medications and did not report a history of cancer or other diseases.
  • She underwent a routine left segmental mastectomy and axillary lymph node dissection that revealed a 4-cm invasive cancer with 1 of 10 axillary lymph nodes positive for metastatic disease.
  • CONCLUSION: A patient with breast cancer and SCD had a painful crisis after receiving paclitaxel as part of her chemotherapy regimen.
  • [MeSH-major] Anemia, Sickle Cell. Antineoplastic Agents, Phytogenic / adverse effects. Paclitaxel / adverse effects. Pain / chemically induced
  • [MeSH-minor] African Americans. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Health Syst Pharm. 2008 Aug 15;65(16):1491
  • (PMID = 18593679.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Al-Tweigeri TA, Ajarim DS, Alsayed AA, Rahal MM, Alshabanah MO, Tulbah AM, Al-Malik OA, Fatani DM, El-Husseiny GA, Elkum NB, Ezzat AA: Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol; 2010 Sep;27(3):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
  • The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC).
  • The primary end point was pathologic complete response (pCR) in breast and axilla.
  • Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4-10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%.
  • Breast conserving surgery was performed in 44%, and MRM in 56%.
  • pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%.
  • The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Estrogens. Female. Genes, erbB-2. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Mastectomy, Modified Radical. Mastectomy, Segmental. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / pathology. Progesterone. Prospective Studies. Radiotherapy, Adjuvant. Tamoxifen / administration & dosage. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 2):10-4 [11284619.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2676-85 [15837982.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):663-7 [9296219.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1189-200 [17701939.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(1):57-61 [16752226.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):56-63 [15598939.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1456-66 [11896092.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):237-44 [11072788.001]
  • [Cites] Br J Surg. 1999 May;86(5):665-8 [10361191.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1005-12 [17047649.001]
  • [Cites] Clin Breast Cancer. 2005 Jun;6(2):163-8 [16001995.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):118S-124S [11560986.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):106S-111S [11560984.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Oncology. 2007;72(1-2):17-26 [17998786.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):968-74 [14997191.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1172-6 [17434897.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 3):28-37 [11301372.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):814-9 [18258991.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):286-92 [9888470.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2600-8 [12829681.001]
  • [Cites] Breast Cancer Res Treat. 1995 Apr;34(1):63-9 [7749161.001]
  • [Cites] Ann Oncol. 2004 May;15(5):751-8 [15111342.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):843-50 [12610183.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):778-85 [18258986.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2988-95 [15860854.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4911-6 [17214361.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2012-8 [17513805.001]
  • [Cites] Clin Breast Cancer. 2004 Dec;5(5):371-6 [15585076.001]
  • (PMID = 19526202.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 4G7DS2Q64Y / Progesterone; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Gupta S, Singh PK, Bisth SS, Bhatt ML, Pant M, Gupta R, Singh S, Negi MP: Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy". Cancer Biol Ther; 2009 Jan;8(1):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy".
  • BACKGROUND: Cervical cancer, in women, is the second most common cancer world wide, next to breast cancer.
  • During the treatment of carcinoma cervix, anemia is selectively frequent and its origin is complex combining hemorrhage, iron deprivation, inflammatory reactions and infection.
  • The objective of this study is to evaluate the role of epoetin in correction of anemia and on treatment outcomes in patients with advanced cervical cancer receiving concurrent chemoradiotherapy.
  • MATERIAL AND METHODS: Total 120, stage IIB to IIIB cervical cancer patients, aged 18-70 years with 9.50-12.50 gm/dl baseline Hb value who were to receive radiotherapy together with cisplatin were randomized to receive either epoetin beta 10,000 IU thrice weekly and oral iron starting 10-15 days before their 5-week course of whole pelvic irradiation and weekly cisplatin (treatment arm) or standard supportive care (control arm), where epoetin beta was not given.
  • CONCLUSIONS: Treatment with epoetin beta safely and effectively corrects anemia in patients with advanced cervical cancer receiving chemoradiotherapy and is not associated with adverse effects on response rate, overall survival, disease free survival and chemoradiotherapy related acute and late toxicities.
  • [MeSH-major] Erythropoietin / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Transfusion. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Recombinant Proteins. Survival Analysis. Survivors. Time Factors. Young Adult


12. Kerr JR: Neonatal effects of breast cancer chemotherapy administered during pregnancy. Pharmacotherapy; 2005 Mar;25(3):438-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal effects of breast cancer chemotherapy administered during pregnancy.
  • A human fetus is most susceptible to teratogenic agents during the first trimester of pregnancy.
  • Cyclophosphamide and doxorubicin are pregnancy category D agents; however, potential benefits may warrant treatment with these agents during pregnancy under special circumstances.
  • During her first trimester of pregnancy, a 37-year-old Caucasian woman was diagnosed with stage IIB infiltrating ductal carcinoma in situ (breast cancer) that was estrogen and progesterone receptor negative and human epidermal growth factor receptor-2 positive.
  • Due to the special considerations of both mother and infant, optimal treatment for patients with pregnancy-associated breast cancer requires the expert opinion of a multidisciplinary care team.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Maternal-Fetal Exchange. Pregnancy Complications, Neoplastic / drug therapy






Advertisement